Most Recent
The Full Court has denied a request by Sanofi that it review a judge's refusal to block Alphapharm from listing its Semglee insulin injector pen on the PBS, calling the pharmaceutical giant's appeal "misconceived".
The Full Federal Court will issue its judgment Friday in French pharmaceutical giant Sanofi's challenge to a judge's refusal to block Alphapharm from listing an insulin injector pen on the PBS, just two weeks after the court heard arguments in the appeal.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
An Australian partner of international law firm Jones Day has moved to the firm's Singapore office to bolster its growing team of international arbitration specialists.
International law firm Jones Day has expanded its intellectual property team in Sydney, hiring experienced patent litigator Andrew Rankine from Ashurst as its second local partner.
The Full Federal Court has expedited an appeal filed Christmas Eve by Sanofi-Aventis of a ruling that denied its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
From a record-setting funder’s cut to the first call for ‘“proportionality”, last year saw a number of groundbreaking judgments approving class action settlements worth more than half a billion dollars. Here are the 10 biggest settlements of 2018, and the law firms and funders that negotiated them.
French pharmaceutical giant Sanofi has appealed a judge's ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
A barrister for two units of embattled wealth manager IOOF and three senior company executives facing claims by APRA have criticised the regulator for filing a broad concise statement and no statement of claim after a three-year investigation.
A judge has denied Sanofi's bid to block Alphapharm from listing its insulin injector pen on the Pharmaceutical Benefit Scheme, saying Sanofi has not established a strong enough case of infringement to justify granting the injunction.